Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Short term Debt (2017 - 2024)

Organogenesis Holdings has reported Short term Debt over the past 8 years, most recently at $6.0 million for Q3 2024.

  • For Q3 2024, Short term Debt rose 8.77% year-over-year to $6.0 million; the TTM value through Sep 2024 reached $6.0 million, up 8.77%, while the annual FY2023 figure was $5.5 million, 20.89% up from the prior year.
  • Short term Debt for Q3 2024 was $6.0 million at Organogenesis Holdings, up from $5.8 million in the prior quarter.
  • Over five years, Short term Debt peaked at $22.5 million in Q2 2021 and troughed at $1.7 million in Q1 2020.
  • A 5-year average of $7.1 million and a median of $5.5 million in 2023 define the central range for Short term Debt.
  • On a YoY basis, Short term Debt climbed as much as 912.3% in 2021 and fell as far as 84.06% in 2021.
  • Year by year, Short term Debt stood at $16.7 million in 2020, then crashed by 84.06% to $2.7 million in 2021, then soared by 70.86% to $4.5 million in 2022, then rose by 20.89% to $5.5 million in 2023, then increased by 8.71% to $6.0 million in 2024.
  • Business Quant data shows Short term Debt for ORGO at $6.0 million in Q3 2024, $5.8 million in Q2 2024, and $5.5 million in Q1 2024.